Shustik, J. (2025) “Unique Toxicities of Novel Myeloma Therapies: Focus on Belantamab Mafodotin, Talquetamab, and Selinexor”, Canadian Hematology Today. Toronto, Canada, 4(3), pp. 24–35. doi: 10.58931/cht.2025.4379.